Investigating Candidate Treatments for Blood Cancers
Today, conducting good clinical trials in hematological malignancies requires an understanding of a rapidly evolving treatment paradigm that is increasingly nuanced, complex and patient-directed. Sponsors developing hematological oncology therapies must capitalize on the principles and infrastructures shared by solid tumor oncology trials while adapting endpoints, study designs and data management as well as considering patients’ experiences to address the particular challenges related to investigating candidate treatments for blood-based cancers.
This paper examines the nuances of effectively and successfully conducting hematological oncology clinical trials. Submit this form for download.